September 2026 Research Update

Across these moderate-strength observational studies in children, symptom patterns in familial Mediterranean fever (FMF) were not uniform: they shifted with age at first symptoms, differed across countries, and tracked with specific MEFV gene variants. Earlier onset tended to line up with more fever and abdominal pain and with a higher burden of certain exon 10 variants, while chest pain and joint symptoms were more common in older-onset groups and in some regional cohorts. Longer-term follow-up in one specific genetic subgroup showed that ongoing attacks over time related to measurable cumulative damage in a minority, including some kidney-related findings.

In a large pediatric cohort (n = 1203), children whose FMF started before age 10 more often had fever and abdominal pain, while those who started at or after age 10 more often had chest pain and arthritis. The older-onset group also had less M694V homozygosity, and statistical modeling linked onset at or after age 10 with lower fever frequency and higher chest pain frequency. [1]

In a nationwide multicenter cohort from Azerbaijan (n = 349), common MEFV variants included M694V, V726A, and R202Q, and fever and abdominal pain were the most frequent symptoms overall. Having at least one M694V allele and having two exon 10 variants (biallelic exon 10 involvement) were linked to earlier symptom onset, including among children with compound heterozygous exon 10 combinations. This supports the idea that the specific location of variants within the MEFV gene (especially exon 10) can relate to when FMF begins. [2]

A bicentric comparison of pediatric patients from Turkiye and Azerbaijan (n = 549) reported that Azerbaijani children had earlier symptom onset but longer diagnostic delay, while Turkish children had more chest pain, more joint pain, higher yearly attack frequency, and higher blood inflammation marker levels. Turkish patients also more often had "confirmatory" exon 10 genotypes, and among exon 10 homozygotes, the Turkish group had higher severity scores and more arthritis. Colchicine response rates were similar across countries, while anti-interleukin-1 treatment was used more often in the Turkish cohort. [3]

In a long follow-up cohort focused on children with one pathogenic exon 10 MEFV variant (n = 274; median follow-up 86 months), abdominal pain and fever were very common, and many also had muscle and joint symptoms. Over time, 8% had cumulative damage as defined in the study, and 2.2% had persistent non-nephrotic protein in the urine without another explanation reported; higher annual attack frequency was linked to cumulative damage. Many children who stopped colchicine later restarted it, showing that treatment patterns can change over time in this subgroup. [4]

For patients and caregivers, these studies mainly help explain why two children with FMF can look different: age at first symptoms, the specific MEFV variant pattern (especially exon 10 and M694V), and region of origin were all linked to differences in fever, belly pain, chest pain, and joint symptoms. The longer-term exon 10 heterozygous follow-up study adds background on what symptoms and measured damage looked like over years in that particular genetic subgroup, but it does not prove what will happen for any one child. Important uncertainties remain, including how well results from one country or genetic subgroup apply to others and whether gene patterns predict long-term outcomes beyond symptom timing and attack frequency.

Across these studies, getting to a Familial Mediterranean fever (FMF) diagnosis often took time, especially when symptoms were not classic or when the first symptoms started very young or later in life. One large pediatric study showed that delays of many months were common and linked to how FMF first showed up, while a small adult case series highlighted that unusual chest-fluid buildup can obscure the diagnosis. A separate genetics study mapped which MEFV gene changes were seen in a regional referral population, but could not tie gene results to symptoms because clinical details were not collected. [5] [6] [7]

In a retrospective review of 1259 children with FMF at a tertiary center, the median time from first symptoms to diagnosis was 17 months. Longer delays were linked to a younger age when symptoms began, and delays were also more common in children whose early symptoms included fever, belly pain, or an erysipelas-like skin rash. Having a known family history of FMF (in parents or siblings) was linked to a shorter time to diagnosis, while the distribution of MEFV variants and symptom severity scores did not differ between shorter and longer delay groups. [5]

In a small case series of six adults over age 50, FMF presented mainly as repeated pleural effusions (fluid around the lungs), an uncommon starting point that can lead to extensive evaluation for other causes. All six had an MEFV gene change called R202Q reported on testing, and most improved after starting colchicine, though two were described as resistant and needed other therapies. Because this report covered only six people and the disease-causing role of R202Q is uncertain, it mainly illustrates how FMF can look atypical in some older adults rather than giving firm estimates. [6]

A molecular study of 611 people referred for suspected FMF in one region of Turkiye found that 62% had at least one MEFV variant, and it described which variants were most frequently detected in that referral population. The authors also applied an exploratory computer-based approach to sort some uncommon variants into categories leaning toward likely harmful or likely benign. Because symptom and examination details were not collected, these results cannot show which variants matched which FMF features or which results would confirm FMF in an individual person. [7]

For patients and caregivers, these papers add context for why FMF can be missed or diagnosed later: symptoms may be nonspecific in young children, and FMF can sometimes show up in unusual ways such as fluid around the lungs in older adults. The strongest evidence here is the large pediatric record review showing that multi-month delays are common and that family history can shorten time to diagnosis, while the adult case series and the regional genetics report mainly serve as background on less typical presentations and on how gene test results can be complex to interpret without detailed clinical information. What remains uncertain is how best to combine symptom patterns and MEFV gene findings to speed diagnosis across different ages and atypical situations, since the genetics study lacked clinical data and the adult report was very small.

Across these papers, AA amyloidosis in Familial Mediterranean fever (FMF) was most consistently linked to sustained inflammation and higher disease activity, and it often showed up through kidney problems. Genetic results were more mixed: one comparative study found genotype frequencies were similar in people with and without amyloidosis, while a case series highlighted that less common or single-copy (heterozygous) gene variants can still be seen in people with AA amyloidosis. [8] [9]

In a single-center Algerian comparison of FMF patients with biopsy-proven AA amyloidosis versus affected relatives without amyloidosis, the most important differences were markers of more active inflammation and attacks: longer attacks (over 72 hours), shorter time between attacks (under 3 months), and higher baseline C-reactive protein (CRP), a blood marker of inflammation. The same study found the common M694I/M694I gene pattern occurred at similar rates in both groups, pointing to inflammation level as a clearer separator than genotype in this cohort. [8]

A French national referral-center cohort that included FMF and other monogenic autoinflammatory diseases (CAPS, MKD, TRAPS) described a high burden once AA amyloidosis developed, with many patients needing kidney transplantation and a substantial death rate during follow-up. In this cohort, AA amyloidosis was diagnosed before the underlying autoinflammatory disease in 40% of patients, especially in the non-FMF conditions, suggesting that delayed recognition can occur. [10]

A case series described patients who had a kidney biopsy for protein in the urine and were unexpectedly found to have AA amyloidosis together with various MEFV gene variants, emphasizing diagnostic challenges and genetic variety. The authors noted that AA amyloidosis was seen in patients carrying less common MEFV variants and in some with heterozygous variants, which can be overlooked when clinicians focus only on the best-known high-risk variants. [9]

For patients and caregivers, these studies mainly reinforce that AA amyloidosis in FMF is closely tied to the overall level of ongoing inflammation and attack pattern, and that kidney involvement is a central concern once amyloidosis develops. They also suggest that genetic results alone may not fully capture risk, and that amyloidosis can sometimes be recognized before the underlying autoinflammatory condition is identified, particularly outside FMF. What remains uncertain is how well these patterns apply across different countries, healthcare settings, and specific MEFV variants, since one study was single-center and another was a case series without a clear comparison group. [8] [10] [9]

Across these studies, the main pattern was that treatment adjustments can make a measurable difference for some people with familial Mediterranean fever (FMF), but the strength of evidence varies. The strongest data came from real-world cohort studies, while the evidence for an oral Janus kinase (JAK) inhibitor came from only three patients. Separately, a large database study suggested that combining colchicine with statins may raise the chance of muscle-related lab changes and myopathy compared with no treatment, with only a small added risk beyond statins alone. [11] [12] [13]

In 103 children with colchicine-resistant FMF and biallelic MEFV exon 10 variants, switching from coated to compressed colchicine was followed by fewer attacks and lower disease activity scores overall. Most children improved across several major attack symptoms, but among those who later needed interleukin-1 (IL-1) inhibitor treatment, fever was the only symptom that decreased significantly after the switch, suggesting the switch may help some children but not all. [11]

In a retrospective report of three adults with colchicine-resistant FMF, the oral JAK inhibitor tofacitinib was followed by complete remission with no attacks during 9 to 12 months of follow-up. No infectious, blood, clotting, or liver-related side effects were observed in these three people, but this was a very small series without a comparison group, so it cannot show how often this would happen in broader FMF populations. [12]

In a large Israeli health-system database study of adults with gout or FMF, statin use was linked to higher rates of elevated muscle enzyme tests and myopathy compared with no treatment, and this was also seen in people using statins together with colchicine. Colchicine alone did not show a clear increase in elevated muscle enzyme tests compared with no treatment, and the additional risk from combining colchicine with a statin appeared small when compared with statin alone. [13]

For patients and caregivers, these papers add context about two different situations: options when FMF remains active despite colchicine, and safety considerations when colchicine is taken with other common medicines like statins. The colchicine-switch study and the statin-safety study are based on real-world cohorts and may reflect everyday care, while the tofacitinib report is early evidence from only three people and mainly serves as background until larger controlled studies are available. Important uncertainties include who is most likely to respond to switching colchicine preparation, and how well results from small, uncontrolled reports translate to longer-term outcomes and broader FMF groups. [11] [12] [13]

Across these studies, researchers looked at blood-based immune signals to see whether they track Familial Mediterranean fever (FMF) activity or related conditions. Interleukin-6 (IL-6) generally moved in the same direction as other inflammation tests and symptom burden, while other signals either did not track attacks or mainly differed in specific overlap conditions. Overall, the evidence is exploratory and based on cross-sectional snapshots, so it cannot show how well these markers predict future flares or complications.

In a pediatric case-control study, children with FMF had higher IL-6 and higher standard inflammation markers than healthy children. IL-6 rose along with disease activity scores, attack frequency, and other inflammation tests, and it was higher in children reporting abdominal pain, fever, chest pain, or joint pain during attacks. [14]

In the same pediatric study, IL-6 levels were also higher in children with two disease-causing MEFV gene changes (homozygous or compound heterozygous) compared with those with a single change, and higher in those carrying the M694V variant. A separate IL-6 gene variant (rs1800795) did not differ between FMF and controls and did not relate to IL-6 levels. [14]

A separate cross-sectional study found that serum 14-3-3eta levels were lower in people with FMF than in healthy controls. However, 14-3-3eta did not differ between people measured during an attack versus outside an attack, and it did not differ between those with and without amyloidosis, suggesting limited value for tracking day-to-day activity or this complication in that dataset. [15]

Another small pediatric study focused on innate lymphoid cells, a type of immune cell, in FMF with and without spondyloarthritis (a form of inflammatory arthritis). Total numbers of these cells were similar across groups, but children with FMF plus spondyloarthritis showed a more "type 2" activation pattern (higher IL-4 and IL-5 in these cells), while spondyloarthritis alone showed different signals in blood and joint fluid (including higher IP-10 and IL-17 in joint fluid). [16]

For patients and caregivers, these papers add context on what researchers are testing as possible ways to measure inflammation in FMF using blood samples (and sometimes joint fluid). Right now, the strongest consistent signal in these studies was that IL-6 tracked with other inflammation tests and symptom burden during attacks in one pediatric group, while 14-3-3eta did not track attack status or amyloidosis in one cross-sectional sample, and immune-cell patterns differed mainly in children who had both FMF and spondyloarthritis. It is still uncertain whether any of these measures can reliably predict future flares or complications, because the studies were cross-sectional, relatively small, and did not follow people over time.

Across these studies, day-to-day living with familial Mediterranean fever (FMF) looked different depending on who was asked and what part of life was measured. In one study, mothers rated their children as more vulnerable than fathers did; in another, parent-reported quality of life differed by gene type and by child sex, while childrens own ratings did not, suggesting a gap between adult and child perspectives. In adults, staying consistent with long-term colchicine use varied, and some social factors seemed to matter more than genetics or reported disease activity.

In a cross-sectional study of 64 children with FMF and their parents, mothers reported higher perceptions of child vulnerability than fathers, and the two parents' scores still tended to move together. A co-diagnosis of PFAPA (Periodic Fever, Aphthous stomatitis, Pharyngitis, and Adenitis) was linked to higher vulnerability scores in fathers, while a specific FMF gene change (M694V) and family history were not linked to higher vulnerability in either parent. [17]

In a multicenter cross-sectional study of 155 children with FMF (ages 5 to 12) and their mothers, parent-reported quality of life was lower when children had two exon 10 gene variants and was also lower for girls than boys. However, children did not report differences in their own quality of life by mutation burden, age, or sex, and caregiver-reported sleep habits and maternal anxiety and depression scores did not differ by mutation burden. Overall, the study highlighted that parent and child reports may not match, even when both are describing the same child's daily experience. [18]

In a cross-sectional study of 104 adults with FMF taking colchicine, about three in ten were classified as low adherers based on a questionnaire measure, while about one in four were classified as high adherers. Younger age and lower income were linked to higher odds of low adherence, while FMF gene type and measured disease activity were not clearly linked in this analysis. The questionnaire scores also lined up moderately with both patient- and physician-rated adherence, suggesting it reflected real-world patterns rather than random answers. [19]

One case report described a 23-year-old woman with FMF who developed extensive central vein blockages that affected access for needed intravenous lines. The report described successful vein reopening procedures and placement of two PICC lines that stayed functional over 7 months, but also noted ongoing clotting and uncontrolled inflammation during follow-up, showing how complicated daily medical needs can become for a small number of people with severe problems. Because this is a single patient, it may not apply to most people with FMF. [20]

For patients and caregivers, these studies mainly help explain why daily life with FMF can feel different depending on whose viewpoint is captured (child vs parent, mother vs father) and why social and life-stage factors may shape routines around long-term medicines. They also show that common genetic categories did not consistently explain differences in family worry, perceived child quality of life, or adult adherence in these snapshots. Because most data here come from cross-sectional studies (a single point in time) and one case report, it remains uncertain how these patterns change over time or how closely they track with flares and longer-term outcomes.